Ipsen (OTCMKTS:IPSEY) PT Raised to €95.00 at Deutsche Bank Aktiengesellschaft

Ipsen (OTCMKTS:IPSEYGet Rating) had its target price hoisted by Deutsche Bank Aktiengesellschaft from €90.00 ($96.77) to €95.00 ($102.15) in a note issued to investors on Thursday, The Fly reports. The brokerage currently has a “hold” rating on the stock.

Several other analysts have also commented on the company. JPMorgan Chase & Co. raised their target price on Ipsen from C$91.00 to C$115.00 in a report on Monday, November 21st. UBS Group raised their target price on Ipsen from €102.00 ($109.68) to €107.00 ($115.05) in a report on Friday, November 4th. Morgan Stanley raised their target price on Ipsen from €84.00 ($90.32) to €86.00 ($92.47) and gave the stock an “underweight” rating in a report on Thursday, October 13th. Societe Generale raised their target price on Ipsen from €139.00 ($149.46) to €142.00 ($152.69) and gave the stock a “buy” rating in a report on Monday, October 31st. Finally, Barclays reissued an “equal weight” rating on shares of Ipsen in a report on Tuesday, December 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $106.00.

Ipsen Price Performance

Ipsen stock opened at $27.64 on Thursday. Ipsen has a 52 week low of $21.17 and a 52 week high of $32.51. The business’s 50-day moving average price is $26.74 and its 200 day moving average price is $25.08.

About Ipsen

(Get Rating)

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents.

Further Reading

The Fly logo

Analyst Recommendations for Ipsen (OTCMKTS:IPSEY)

Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.